CR20210281A - Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr - Google Patents

Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr

Info

Publication number
CR20210281A
CR20210281A CR20210281A CR20210281A CR20210281A CR 20210281 A CR20210281 A CR 20210281A CR 20210281 A CR20210281 A CR 20210281A CR 20210281 A CR20210281 A CR 20210281A CR 20210281 A CR20210281 A CR 20210281A
Authority
CR
Costa Rica
Prior art keywords
compounds
methods
pharmaceutical compositions
kinase inhibitors
atr kinase
Prior art date
Application number
CR20210281A
Other languages
English (en)
Inventor
Cameron Black
Stéphane Dorich
Abbas Abdoli
Miguel St-Onge
Lee Fader
Audrey Picard
Sheldon N Crane
Jean-François Truchon
Cyrus M Lacbay
Vouy Linh Truong
Stéphanie Lanoix
Paul Jones
Original Assignee
Repare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repare Therapeutics Inc filed Critical Repare Therapeutics Inc
Publication of CR20210281A publication Critical patent/CR20210281A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuestos y sales farmacéuticamente aceptables de estos que se pueden usar en el tratamiento de sujetos que los necesitan. Los compuestos descritos en la presente pueden ser inhibidores de la proteína cinasa relacionada con ataxia telangiectasia y RAD3 (ATR). También se describen composiciones farmacéuticas que contienen los compuestos o sales farmacéuticamente aceptables de estos y métodos para su preparación y uso.
CR20210281A 2018-10-30 2019-10-30 Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr CR20210281A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752873P 2018-10-30 2018-10-30
US201962877177P 2019-07-22 2019-07-22
PCT/CA2019/051539 WO2020087170A1 (en) 2018-10-30 2019-10-30 Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors

Publications (1)

Publication Number Publication Date
CR20210281A true CR20210281A (es) 2021-10-25

Family

ID=70461742

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210281A CR20210281A (es) 2018-10-30 2019-10-30 Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr

Country Status (17)

Country Link
US (2) US12264155B2 (es)
EP (1) EP3873905A4 (es)
JP (2) JP2022510501A (es)
KR (1) KR20210097124A (es)
CN (2) CN113454080B (es)
AU (1) AU2019373416A1 (es)
BR (1) BR112021008336A2 (es)
CA (1) CA3118218A1 (es)
CR (1) CR20210281A (es)
EC (1) ECSP21038390A (es)
IL (1) IL282801A (es)
MA (1) MA54091A (es)
MX (1) MX2021005012A (es)
PH (1) PH12021550992A1 (es)
SG (1) SG11202104460UA (es)
WO (1) WO2020087170A1 (es)
ZA (1) ZA202103587B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022510501A (ja) 2018-10-30 2022-01-26 リペア セラピューティクス インコーポレイテッド 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法
CN112142744A (zh) 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
AU2020317381A1 (en) * 2019-07-22 2022-02-10 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
BR112022011426A2 (pt) * 2019-12-11 2022-08-30 Repare Therapeutics Inc Uso de inibidores de atr em combinação com inibidores de parp
EP4077322A1 (en) * 2019-12-18 2022-10-26 Intervet International B.V. Anthelmintic compounds comprising azaindoles structure
TW202214642A (zh) * 2020-07-02 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 咪唑并嘧啶類衍生物、其製備方法及其在醫藥上的應用
KR20230039675A (ko) * 2020-07-13 2023-03-21 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Atr 키나제 억제제로 사용되는 피라졸로피리미딘 화합물
IL300261A (en) * 2020-08-07 2023-03-01 Antengene Discovery Ltd ATR inhibitors and their uses
CN116234551A (zh) * 2020-09-27 2023-06-06 南京明德新药研发有限公司 一类1,7-萘啶类化合物及其应用
EP4330426A4 (en) * 2021-04-28 2025-06-04 Repare Therapeutics Inc. Methods for treating cancer with biallelic loss of function or gene overexpression mutation
AU2022271549A1 (en) * 2021-05-12 2023-11-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Sulfoximine-containing atr inhibitor compound
IL309388A (en) * 2021-06-16 2024-02-01 Repare Therapeutics Inc Combining ATR inhibitors and PARP inhibitors for cancer treatment
AU2022316931A1 (en) * 2021-07-27 2024-03-14 Littdd Medicines Ltd 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof
CA3227336A1 (en) * 2021-08-11 2023-02-16 Yuli Xie Naphthyridine derivative as atr inhibitor and method for preparing same
WO2023109883A1 (zh) * 2021-12-15 2023-06-22 上海翊石医药科技有限公司 一类芳杂环取代的化合物及其制备方法和用途
EP4504208A1 (en) * 2022-04-07 2025-02-12 Repare Therapeutics Inc. Methods of using atr inhibitors
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
TW202440598A (zh) 2022-12-07 2024-10-16 瑞士商赫孚孟拉羅股份公司 Ａｔｒ抑制劑之結晶鹽形式
CN119143753B (zh) * 2023-06-14 2026-01-02 石药集团中奇制药技术（石家庄）有限公司 一种杂环类抗肿瘤化合物的盐及其晶型
WO2025057106A1 (en) * 2023-09-12 2025-03-20 Repare Therapeutics Inc. Process and compounds for preparing camonsertib and its salts
AU2024350153A1 (en) * 2023-09-27 2026-04-30 Beyang Therapeutics Co., Ltd. Menin-mll interaction inhibitor and preparation method therefor, and application
TW202545519A (zh) * 2024-05-15 2025-12-01 俄羅斯聯邦商拜奧卡德聯合股份公司 共濟失調毛細血管擴張症和Ｒａｄ３相關激酶抑制劑

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05006B1 (et) 1999-01-11 2008-04-15 Agouron Pharmaceuticals, Inc. Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid
US20060276497A1 (en) 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US20040048866A1 (en) * 2002-03-08 2004-03-11 Teodozyj Kolasa Indazole derivatives that are activators of soluble guanylate cyclase
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
PL1660095T3 (pl) 2003-07-25 2010-07-30 Cancer Research Tech Ltd Tricykliczne inhibitory PARP
TWI338000B (en) 2003-12-01 2011-03-01 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
AU2008273892A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
MX2010003564A (es) 2007-10-03 2010-09-10 Eisai Inc Compuestos inhibidores de poli(adenosina-5'-difosfo-ribosa)polimer asa (parp), composiciones y metodos de uso.
JP2011503111A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
US8012976B2 (en) 2008-08-06 2011-09-06 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
BRPI0924084B1 (pt) 2008-12-19 2021-12-21 Vertex Pharmaceuticals Incorporated Derivados de pirazina e composição farmacêutica que os compreende
US20110053923A1 (en) 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
RS61281B1 (sr) * 2009-12-31 2021-02-26 Hutchison Medipharma Ltd Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora
DK3150610T3 (da) 2010-02-12 2019-11-04 Pfizer Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on
ES2528269T3 (es) 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2012138938A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
US9073924B2 (en) * 2011-09-13 2015-07-07 Glaxosmithkline Llc Azaindazoles
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013095761A1 (en) * 2011-12-20 2013-06-27 Glaxosmithkline Llc Imidazopyridine derivatives as pi3 kinase inhibitors
US20140044802A1 (en) 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CA2939219C (en) 2014-02-11 2023-02-28 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
TWI700283B (zh) * 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
WO2016061097A1 (en) 2014-10-13 2016-04-21 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
HRP20210403T1 (hr) 2015-04-29 2021-10-29 Janssen Pharmaceutica Nv Azabenzimidazoli i njihova uporaba kao modulatora ampa receptora
US10538522B2 (en) 2015-05-14 2020-01-21 The Regents Of The University Of California Brassinosteroid mimetics
WO2017118734A1 (en) 2016-01-08 2017-07-13 The Institute Of Cancer Research: Royal Cancer Hospital Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer
CA3011189C (en) * 2016-01-14 2024-02-20 Bayer Pharma Aktiengesellschaft 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
WO2017133657A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
CA3025220A1 (en) 2016-05-24 2017-11-30 Merck Patent Gmbh Tricyclic heterocylic derivatives
EP3585365B1 (en) 2017-02-24 2021-08-25 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors with parp inhibitors
JOP20190197A1 (ar) 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
CN111886224B (zh) 2017-08-17 2024-07-23 德州大学系统董事会 Atr激酶的杂环抑制剂
IL281212B2 (en) 2018-09-07 2023-12-01 Merck Patent Gmbh 5-Morpholin-4-yl-pyrazolo[4,3-B]pyridine derivatives and their use
JP2022510501A (ja) 2018-10-30 2022-01-26 リペア セラピューティクス インコーポレイテッド 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法
CN112142744A (zh) 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
AU2020317381A1 (en) 2019-07-22 2022-02-10 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
BR112022011426A2 (pt) 2019-12-11 2022-08-30 Repare Therapeutics Inc Uso de inibidores de atr em combinação com inibidores de parp
EP4330426A4 (en) 2021-04-28 2025-06-04 Repare Therapeutics Inc. Methods for treating cancer with biallelic loss of function or gene overexpression mutation
JP2024520141A (ja) 2021-06-04 2024-05-21 リペア セラピューティクス インコーポレイテッド 結晶形、それを含有する組成物、およびそれらの使用方法
IL309388A (en) 2021-06-16 2024-02-01 Repare Therapeutics Inc Combining ATR inhibitors and PARP inhibitors for cancer treatment
WO2023193110A1 (en) 2022-04-07 2023-10-12 Repare Therapeutics Inc. Methods of identifying cancers having a biallelic loss of function mutation
EP4504208A1 (en) 2022-04-07 2025-02-12 Repare Therapeutics Inc. Methods of using atr inhibitors
TW202440598A (zh) 2022-12-07 2024-10-16 瑞士商赫孚孟拉羅股份公司 Ａｔｒ抑制劑之結晶鹽形式

Also Published As

Publication number Publication date
BR112021008336A2 (pt) 2021-08-03
SG11202104460UA (en) 2021-05-28
US12264155B2 (en) 2025-04-01
KR20210097124A (ko) 2021-08-06
JP2024105340A (ja) 2024-08-06
CN113454080B (zh) 2025-10-28
US20210277002A1 (en) 2021-09-09
AU2019373416A1 (en) 2021-06-10
WO2020087170A1 (en) 2020-05-07
MA54091A (fr) 2021-09-15
US20250179070A1 (en) 2025-06-05
IL282801A (en) 2021-06-30
JP2022510501A (ja) 2022-01-26
EP3873905A1 (en) 2021-09-08
CA3118218A1 (en) 2020-05-07
ECSP21038390A (es) 2021-08-31
MX2021005012A (es) 2021-07-21
EP3873905A4 (en) 2022-08-17
CN120665067A (zh) 2025-09-19
CN113454080A (zh) 2021-09-28
ZA202103587B (en) 2025-09-25
PH12021550992A1 (en) 2021-10-04

Similar Documents

Publication Publication Date Title
ZA202103587B (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
MX2022012178A (es) Compuestos, composiciones farmaceuticas y metodos para la preparacion de compuestos y para su uso.
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
MY187047A (en) Selective pyy compounds and uses thereof
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12015502792A1 (en) Crystalline bromodomain inhibitors
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
WO2016109217A3 (en) Btk inhibitors
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
WO2016140933A3 (en) Immediate release soluble ibuprofen compositions
BR112017021669A2 (pt) formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12018502139A1 (en) Phosphaplatin liquid formulations
PH12020551493A1 (en) Triazacyclododecansulfonamide (``tcd``)-based protein secretion inhibitors
EA201992303A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1